Interventional News covered a whole range of the specialty’s news during 2022, but readers’ attention was most piqued by acquisitions (Boston Scientific’s of Obsidio and Bentley’s of the GoBack catheter); study results from meetings that highlighted the “potential” and “promise” of both renal denervation and prostatic artery embolization (PAE); and the launch of a first-in-human trial of a sirolimus drug-coated balloon (DCB) for peripheral indication.
In August, Inari Medical announced planned enrolment of the DEFIANCE randomised controlled trial (RCT), which is designed to compare the clinical outcomes of patients with iliofemoral deep vein thrombosis (DVT) treated with the ClotTriever system versus anticoagulation only.
2) Boston Scientific announces acquisition of Obsidio
Also in August, Boston Scientific shared the news of the acquisition of Obsidio, a privately held company that has developed the Gel Embolic Material (GEM) technology used for embolization of blood vessels in the peripheral vasculature.
Late-breaking trial data presented at EuroPCR 2022 (17–20 May, Paris, France) underscored the potential of renal denervation as an adjunctive therapy to treat hypertension, complementing existing first-line treatments including lifestyle modifications and medication, attendees of the conference heard.
4) “Promising” 10-year findings on PAE for BPH presented at ET 2022
Tiago Bilhim (Saint Louis Hospital, Lisbon, Portugal) presented during the Scientific Paper session at this year’s European Conference on Embolotherapy (22–25 June, Nice, France), and won the award of best abstract for his and co-authors’ ‘Long-term outcome of prostatic artery embolization for patients with benign prostatic hyperplasia’.
5) BD launches first-in-human trial of a peripheral sirolimus drug-coated balloon
Again in August, BD announced the start of enrolment in the PREVISION first-in-human trial, a prospective, multicentre, single arm, non-randomised study designed to evaluate the safety of the BD sirolimus DCB in the treatment of peripheral arterial disease (PAD) in the femoropopliteal arteries.
In November, Otsuka Medical Devices and ReCor Medical, a subsidiary of Otsuka, shared the news that they had filed a pre-market approval (PMA) application to the US Food and Drug Administration (FDA) for the Paradise ultrasound renal denervation (uRDN) system in the treatment of uncontrolled hypertension.
7) Bentley acquires GoBack catheter from Upstream Peripheral Medical Technologies
Bentley announced in September that it had acquired the rights of the GoBack catheter from Upstream Peripheral Technologies.
8) Medtronic receives CE mark for first balloon-expandable covered stent for ChEVAR
September also saw Medtronic share that it received CE mark for its Radiant balloon-expandable covered stent, the first and currently, only, covered stent indicated for use in chimney endovascular aneurysm repair (ChEVAR) with the Endurant II/IIs stent graft system.
9) Non-surgical treatment found to provide long-term relief for carpal tunnel syndrome
A minimally invasive treatment for carpal tunnel syndrome provides complete and long-term relief to patients without the use of corticosteroids, according to research presented at the annual meeting of the Radiological Society of North America (RSNA; 27 November–1 December, Chicago, USA).
10) For some small kidney cancers, freezing is more effective than heat
For patients with early-stage renal cell carcinomas (RCCs) that measure between 3 and 4cm, cryoablation yields a lower risk of cancer-related death compared to thermal ablation, reports a preliminary study in the Journal of Urology published in November.
